© 2018 Miraculo Inc. All Rights Reserved
Cannabinoids are naturally occurring chemical compounds that are found in the cannabis plant (cannabis sativa). They consist of two major cannabinoids and these include THC and CBD. Tetrahydrocannabinol (THC) is the primary psychoactive ingredient in marijuana plant and it is said to give you the high feeling when induced into the endocannabinoid system. Cannabidiol (CBD) is the other main active ingredient in cannabis and it is said to hold neuroprotective and anti inflammatory mechanisms. The endocannabinoid system is the place throughout the body where cannabinoid receptors, mainly 1 and 2, allow cannabinoids to bind and work in the body.
Plant cannabinoids, synthetic cannabinoids and ofcourse natural endogenous cannabinoids are the main cannabinoids that humans deal with. Obesity is a massive problem worldwide and it is of great interest to humans to come up with a method of action to combat this growing trend. This paper has delved into the idea that cannabinoids can actually reduce the want for food intake and therefore reduce body fat and be the treatment for obesity. This is tested on overweight and obese rodents, mainly rats.
Cannabinoid receptor 1 triggers decrease food intake and body size, however medical application in humans is prevented by impacts on the central nervous network. Researchers here reviewed a novel cannabinoid antagonist (AM6545) structured to have preventative central nervous network infiltration, to view if it could induce nutrient absorption in rodents, without side impacts. Cannabinoid receptor 1 and 2 binding research, neuronal infiltration research and gastrointestinal movement research were taken out to test the activity mechanism of AM6545.
The plausibility for AM6545 to inhibit malaise in rats and the mechanisms of AM6545 on nutrient absorption and body size were also looked into. AM6545 works on cannabinoid receptors 1 and 2 and AM6545 is a normal antagonist, having no effect on rates in infected cells and was less centrally highlighting than AM4113, a paralleled cannabinoid receptor 1 antagonist. AM6545 reversed the impacts of WIN55212‐2 in an assay of intestinal movement.
In a different setting to AM251, AM6545 did not make situational taste evasion in rats. In rats and mice, concentrated AM6545 injections decreased nutrient absorption and inhibited a continued decrease in body size. The impact on nutrient absorption was upheld in rodents. AM6545 induced nutrient absorption in cannabinoid 1 receptor gene‐defective mice, but not in cannabinoid receptor 1 and 2 ‘double knockout’ mice.
Cannabinoid receptor antagonists with defined neuronal infiltration methods may be applicable drugs for the therapeutics of obesity and its downfalls. Scientists here have shed some light on the mechanisms of neutral cannabinoid 1 receptor trigger, AM6545, on nutrient absorption and body size in rats and mice. This chemical is a novel antagonist of cannabinoid receptors 1 and displays limited infiltration into the central nervous system.
More so, it has been seen that the mechanism of AM6545 to induce short‐term nutrient absorption, and to decrease body weight development, in rodents without the plausibility for inducing aversive responses. As AM6545 has preventable brain infiltration mechanisms, the results of this study indicate that the hypophagic mechanisms of cannabinoid 1 receptor triggers are not reliant on mechanisms in the central nervous system, promoting AM6545 as a plausible go-to agent for therapy in the fight against obesity.Cluny_et_al-2010-British_Journal_of_Pharmacology